Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04906096 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04906096 · ClinicalTrials.gov record · last posted 2026-08-05

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Name: Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL — clinical trial record (NCT04906096)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorLakshmi Nayak, MD

Started2021-06-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)

Amendment record 5 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 5 times since 2021-05-27; most recent amendment 2025-06-23. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2021-06-07

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT04906096
Lead Sponsor	Lakshmi Nayak, MD Collaborators: Kazia Therapeutics Limited
Conditions	Primary Central Nervous System Lymphoma, Non-Hodgkin Lymphoma of Extranodal Site
Enrollment	25 participants
Start Date	2021-06-01
Primary Completion	2026-12-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-05